Common use of Sublicense Income Clause in Contracts

Sublicense Income. Subject to Section 5.6(f), the Opt-In Party will pay to Regulus a portion of the Sublicense Income received by the Opt-In Party or its Affiliates, in accordance with the following table: Sublicense agreement initially entered into Percentage of during this timeframe: Sublicense Income Prior to Completion of first Phase IIa Clinical Trial [***] % After Completion of first Phase IIa Clinical Trial, but prior to completion of first Phase III Clinical Trial [***] % After Completion of first Phase III Clinical Trial [***] %

Sublicense Income. Subject to Section 5.6(f), the Opt-In Party will pay to Regulus a portion of the Sublicense Income received by the Opt-In Party or its Affiliates, in accordance with the following table: Sublicense agreement initially entered into Percentage of during this timeframe: Percentage of Sublicense Income Prior to Completion of first Phase IIa Clinical Trial [***] ]% After Completion of first Phase IIa Clinical Trial, but prior to completion of first Phase III Clinical Trial [***] ]% After Completion of first Phase III Clinical Trial [***] ]%

Sublicense Income. Subject to Section 5.6(f), the Opt-In Party will pay to Regulus a portion of the Sublicense Income received by the Opt-In Party or its Affiliates, in accordance with the following table: Sublicense agreement initially entered into Percentage of during this timeframe: Sublicense Income Prior to Completion of first Phase IIa Clinical Trial [...***...] % After Completion of first Phase IIa Clinical Trial, but prior to completion of first Phase III Clinical Trial [...***...] % After Completion of first Phase III Clinical Trial [...***...] %

Sublicense Income. Subject to Section 5.6(f), the Opt-In Party will pay to Regulus a portion of the Sublicense Income received by the Opt-In Party or its Affiliates, in accordance with the following table: Sublicense agreement initially entered into Percentage of during this timeframe: Sublicense Income Prior to Completion of first Phase IIa Clinical Trial [***] ]% After Completion of first Phase IIa Clinical Trial, but prior to completion of first Phase III Clinical Trial [***] ]% After Completion of first Phase III Clinical Trial [***] ]%

Sublicense Income. Subject to Section 5.6(f), the Opt-In Party will pay to Regulus a portion of the Sublicense Income received by the Opt-In Party or its Affiliates, in accordance with the following table: Sublicense agreement initially entered into Percentage of during this timeframe: Percentage of Sublicense Income Prior to Completion of first Phase IIa Clinical Trial [...***] ...]% After Completion of first Phase IIa Clinical Trial, but prior to completion of first Phase III Clinical Trial [...***] ...]% After Completion of first Phase III Clinical Trial [...***] %...]% ***Confidential Treatment Requested

Sublicense Income. Subject to Section 5.6(f), the Opt-In Party will pay to Regulus a portion of the Sublicense Income received by the Opt-In Party or its Affiliates, in accordance with the following table: Sublicense agreement initially entered into Percentage of during this timeframe: Percentage of Sublicense Income Prior to Completion of first Phase IIa Clinical Trial [...***] ...]% After Completion of first Phase IIa Clinical Trial, but prior to completion of first Phase III Clinical Trial [...***] ...]% After Completion of first Phase III Clinical Trial [...***] ...]%

Sublicense Income. Subject to Section 5.6(f), the Opt-In Party will pay to Regulus a portion of the Sublicense Income received by the Opt-In Party or its Affiliates, in accordance with the following table: Sublicense agreement initially entered into Percentage of during this timeframe: Percentage of Sublicense Income Prior to Completion of first Phase IIa Clinical Trial [***] % After Completion of first Phase IIa Clinical Trial, but prior to completion of first Phase III Clinical Trial [***] % After Completion of first Phase III Clinical Trial [***] %

Sublicense Income. Subject to Section 5.6(f), the Opt-In Party will pay to Regulus a portion of the Sublicense Income received by the Opt-In Party or its Affiliates, in accordance with the following table: Sublicense agreement initially entered into Percentage of during this timeframe: Sublicense Income Prior to Completion of first Phase IIa Clinical Trial [...***...] % After Completion of first Phase IIa Clinical Trial, but prior to completion of first Phase III Clinical Trial [...***...] % After Completion of first Phase III Clinical Trial [...***...] %% ***Confidential Treatment Requested